Patient-Reported Outcomes After Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine Versus Staying on Oral Antiretroviral Therapy: A Prospective Korean Cohort Study
Open Access
- 1 January 2027
- journal article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Abstract
Shin DH, et al. J Korean Med Sci. 2027 Mar;42:e71. https://doi.org/10.3346/jkms.2027.42.e71Keywords
This publication has 31 references indexed in Scilit:
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA PanelJAMA, 2025
- Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinicsJournal of the International AIDS Society, 2024
- Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR StudyAIDS and Behavior, 2024
- Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIVAdvances in Therapy, 2023
- Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)The Patient - Patient-Centered Outcomes Research, 2021
- Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives StudyAIDS and Behavior, 2020
- Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 WeeksAIDS and Behavior, 2020
- Psychometric Evaluation Of The Revised Hiv Treatment Satisfaction Questionnaire (Hivtsq)Value in Health, 2016
- Minimal Clinically Important DifferenceJAMA, 2014
- ANCOVA versus change from baseline had more power in randomized studies and more bias in nonrandomized studiesJournal of Clinical Epidemiology, 2006